SHR902275 是一种有效、选择性和口服活性Raf抑制剂，靶向 Ras 突变癌症。 对于 cRaf、bRafwt和 bRafV600E，SHR902275 对 cRaf, bRafwt, bRafV600E的IC50分别为 1.6 nM、10 nM、5.7 nM。 SHR902275 显示细胞生长抑制作用，对 H358、A375、Calu6 和 SK-MEL2 细胞的 GI50分别为 1.5 和 0.17 nM、0.4 nM 和 0.32 nM .

SHR902275 is a potent, selective, and orally active RAF inhibitor targeting RAS mutant cancers. SHR902275 has IC 50 s of 1.6 nM, 10 nM, and 5.7 nM for cRAF, bRAF wt, and bRAF V600E, respectively. SHR902275 shows cell growth inhibition with GI 50 s of 1.5 and 0.17 nM, 0.4 nM and 0.32 nM for H358, A375, Calu6, and SK-MEL2 cells respectively [1].

2695506-82-0

C26H23F3N4O4

512.48

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years